Login to Your Account



$710M for Elotuzumab

PDL Could Get $1.2B from BMS for Two Early Stage Antibodies

By Trista Morrison


Thursday, August 21, 2008
After struggling through a year of shifting business strategies, PDL BioPharma Inc. signed an antibody deal with Bristol-Myers Squibb Co. that could be worth nearly $1.16 billion. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription